Joseph Mendicino,* Fredrich Leibach, and Sesha Reddy, 1978 "Role of Enzyme Interactions in the Regulation of Gluconeogenesis: Phosphorylation of Fructose 1,6-Bisphosphataseand Phosphofructokinase by Kidney Protein Kinase?"
http://pubs.acs.org.lib-proxy.calvin.edu/doi/pdf/10.1021/bi00615a012
2. The inhibition of Fructose 1,6-bisphosphatase is maybe a form of controlling diabetes. Fructose 1,6-bisphosphatase is one of the enzymes used in the synthesis of glucose. They looked at three possible inhibitor points: 1. the active site for 1,6-bisphosphatase, 2. An allosteric binding site for AMP, and 3. A tetrameric binding site at the dimer interface. The leading compounds for inhibiting fructose 1,6-bisphosphates is organofluorines. Through this research they found three inhibitors. It is a really interesting that an inhibitor of this protein can help treat diseases like diabetes.
Aleksandra Rudnitskaya, Ken Huynh, Be ́la To ̈ro ̈k,* and Kimberly Stieglitz*
Novel Heteroaromatic Organofluorine Inhibitors of Fructose-1,6-bisphosphatase
http://pubs.acs.org.lib-proxy.calvin.edu/doi/pdf/10.1021/jm800720a
3. Fructose 1,6-bisphosphatase has multiple subunits that allows it to change from R state to T state. This paper looks at the conformational change of the protein. The dimers shift 17 degrees from each other. This change the Arg-22 residue to go from interacting with Glu-108 and Arg-110 to Thr-27 and Glu-29. To see if the arginine was important part of the protein functionality, they converted it to an alanine. They looked at the differences in the catalytic ability of R-state vs. T state. Through their research they found that the Arg22 to Ala has no effect on the enzyme and the R-state enhances catalytic potential. This research shows that the arginine is only part of the catalytic properties of the enzyme.
Guqiang Lu, Mark K. Williams, Eugene L. Giroux, and Evan R. Kantrowitz"
Fructose-1,6-bisphosphatase: Arginine-22 Is Involved in Stabilization of the T Allosteric State?
http://pubs.acs.org.lib-proxy.calvin.edu/doi/pdf/10.1021/bi00041a002
Over eight years of successful operation in the pharmaceutical industry has enabled us to possess a full-bodied array of building blocks in numerous pack sizes. α-Amyloid Precursor Protein Modulator
ReplyDelete